AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O'Hare, William C. Shakespeare, Xiaotian Zhu, Christopher A. Eide, Victor M. Rivera, Frank Wang, Lauren T. Adrian, Tianjun Zhou, Wei Sheng Huang, Qihong Xu, Chester A. Metcalf, Jeffrey Tyner, Marc Loriaux, Amie S. Corbin, Scott Wardwell, Yaoyu Ning, Jeffrey A. Keats, Yihan Wang, Raji Sundaramoorthi, Mathew ThomasDong Zhou, Joseph Snodgrass, Lois Commodore, Tomi K. Sawyer, David C. Dalgarno, Michael W N Deininger, Brian Druker, Tim Clackson

Research output: Contribution to journalArticle

686 Citations (Scopus)

Abstract

Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib. Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compound mutants selected on sequential inhibitor therapy remain major clinical challenges. We report design and preclinical evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants. AP24534 inhibited all tested BCR-ABL mutants in cellular and biochemical assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens. Our work supports clinical evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.

Original languageEnglish (US)
Pages (from-to)401-412
Number of pages12
JournalCancer Cell
Volume16
Issue number5
DOIs
StatePublished - Nov 6 2009

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mutation
Phosphotransferases
Therapeutics
Mutagenesis
Recurrence
ponatinib
Growth
Neoplasms

Keywords

  • CHEMBIO
  • HUMDISEASE

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. / O'Hare, Thomas; Shakespeare, William C.; Zhu, Xiaotian; Eide, Christopher A.; Rivera, Victor M.; Wang, Frank; Adrian, Lauren T.; Zhou, Tianjun; Huang, Wei Sheng; Xu, Qihong; Metcalf, Chester A.; Tyner, Jeffrey; Loriaux, Marc; Corbin, Amie S.; Wardwell, Scott; Ning, Yaoyu; Keats, Jeffrey A.; Wang, Yihan; Sundaramoorthi, Raji; Thomas, Mathew; Zhou, Dong; Snodgrass, Joseph; Commodore, Lois; Sawyer, Tomi K.; Dalgarno, David C.; Deininger, Michael W N; Druker, Brian; Clackson, Tim.

In: Cancer Cell, Vol. 16, No. 5, 06.11.2009, p. 401-412.

Research output: Contribution to journalArticle

O'Hare, T, Shakespeare, WC, Zhu, X, Eide, CA, Rivera, VM, Wang, F, Adrian, LT, Zhou, T, Huang, WS, Xu, Q, Metcalf, CA, Tyner, J, Loriaux, M, Corbin, AS, Wardwell, S, Ning, Y, Keats, JA, Wang, Y, Sundaramoorthi, R, Thomas, M, Zhou, D, Snodgrass, J, Commodore, L, Sawyer, TK, Dalgarno, DC, Deininger, MWN, Druker, B & Clackson, T 2009, 'AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance', Cancer Cell, vol. 16, no. 5, pp. 401-412. https://doi.org/10.1016/j.ccr.2009.09.028
O'Hare, Thomas ; Shakespeare, William C. ; Zhu, Xiaotian ; Eide, Christopher A. ; Rivera, Victor M. ; Wang, Frank ; Adrian, Lauren T. ; Zhou, Tianjun ; Huang, Wei Sheng ; Xu, Qihong ; Metcalf, Chester A. ; Tyner, Jeffrey ; Loriaux, Marc ; Corbin, Amie S. ; Wardwell, Scott ; Ning, Yaoyu ; Keats, Jeffrey A. ; Wang, Yihan ; Sundaramoorthi, Raji ; Thomas, Mathew ; Zhou, Dong ; Snodgrass, Joseph ; Commodore, Lois ; Sawyer, Tomi K. ; Dalgarno, David C. ; Deininger, Michael W N ; Druker, Brian ; Clackson, Tim. / AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. In: Cancer Cell. 2009 ; Vol. 16, No. 5. pp. 401-412.
@article{556178f85dfb469299601fde3889350f,
title = "AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance",
abstract = "Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib. Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compound mutants selected on sequential inhibitor therapy remain major clinical challenges. We report design and preclinical evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants. AP24534 inhibited all tested BCR-ABL mutants in cellular and biochemical assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens. Our work supports clinical evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.",
keywords = "CHEMBIO, HUMDISEASE",
author = "Thomas O'Hare and Shakespeare, {William C.} and Xiaotian Zhu and Eide, {Christopher A.} and Rivera, {Victor M.} and Frank Wang and Adrian, {Lauren T.} and Tianjun Zhou and Huang, {Wei Sheng} and Qihong Xu and Metcalf, {Chester A.} and Jeffrey Tyner and Marc Loriaux and Corbin, {Amie S.} and Scott Wardwell and Yaoyu Ning and Keats, {Jeffrey A.} and Yihan Wang and Raji Sundaramoorthi and Mathew Thomas and Dong Zhou and Joseph Snodgrass and Lois Commodore and Sawyer, {Tomi K.} and Dalgarno, {David C.} and Deininger, {Michael W N} and Brian Druker and Tim Clackson",
year = "2009",
month = "11",
day = "6",
doi = "10.1016/j.ccr.2009.09.028",
language = "English (US)",
volume = "16",
pages = "401--412",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

AU - O'Hare, Thomas

AU - Shakespeare, William C.

AU - Zhu, Xiaotian

AU - Eide, Christopher A.

AU - Rivera, Victor M.

AU - Wang, Frank

AU - Adrian, Lauren T.

AU - Zhou, Tianjun

AU - Huang, Wei Sheng

AU - Xu, Qihong

AU - Metcalf, Chester A.

AU - Tyner, Jeffrey

AU - Loriaux, Marc

AU - Corbin, Amie S.

AU - Wardwell, Scott

AU - Ning, Yaoyu

AU - Keats, Jeffrey A.

AU - Wang, Yihan

AU - Sundaramoorthi, Raji

AU - Thomas, Mathew

AU - Zhou, Dong

AU - Snodgrass, Joseph

AU - Commodore, Lois

AU - Sawyer, Tomi K.

AU - Dalgarno, David C.

AU - Deininger, Michael W N

AU - Druker, Brian

AU - Clackson, Tim

PY - 2009/11/6

Y1 - 2009/11/6

N2 - Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib. Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compound mutants selected on sequential inhibitor therapy remain major clinical challenges. We report design and preclinical evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants. AP24534 inhibited all tested BCR-ABL mutants in cellular and biochemical assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens. Our work supports clinical evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.

AB - Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib. Despite three approved therapeutic options, the cross-resistant BCR-ABLT315I mutation and compound mutants selected on sequential inhibitor therapy remain major clinical challenges. We report design and preclinical evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants. AP24534 inhibited all tested BCR-ABL mutants in cellular and biochemical assays, suppressed BCR-ABLT315I-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens. Our work supports clinical evaluation of AP24534 as a pan-BCR-ABL inhibitor for treatment of CML.

KW - CHEMBIO

KW - HUMDISEASE

UR - http://www.scopus.com/inward/record.url?scp=70350507997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350507997&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2009.09.028

DO - 10.1016/j.ccr.2009.09.028

M3 - Article

C2 - 19878872

AN - SCOPUS:70350507997

VL - 16

SP - 401

EP - 412

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 5

ER -